Cancer cells often travel throughout the body and cause new tumours in individuals with advanced breast cancer - a process called metastasis - commonly resulting in malignant bone tumours. What the Princeton research has uncovered is the exact mechanism that lets the travelling tumour cells disrupt normal bone growth. By zeroing in on the molecules involved, and particularly a protein called "Jagged1" that sends destructive signals to cells, the research team has opened the door to drug therapies that could block this disruptive process. Doctors at other medical centres who have reviewed the research have found it promising.
"Right now we don't have many treatments to offer these patients," said Yibin Kang, an associate professor of molecular biology at Princeton who led the research team. "Doctors can manage the symptoms of this bone cancer, but they can't do much more. Our findings suggest there could be a new way of treatment," one that could slow or halt these bone tumours.
Breast cancer spreads to the bone in 70 to 80% of patients with advanced breast cancer, and it can also spread to the brain, lung and liver. Metastatic bone cancer is also a frequent occurrence among patients with advanced prostate, lung and skin cancers. In findings that will be published online in the journal Cancer Cell on Feb. 3, the team's research shows that breast tumour cells are able to give bone cells the wrong instructions through a process known as cell signalling - with disastrous effects for the patient.
The billions of cells in a living human body must communicate to develop, repair tissue and effectively maintain normal physiological functions. Cell signalling is part of a complex system that enables them to do that but, in patients with cancer, the relationship between signalling molecules and the molecules that communicate with them has gone awry.
Signalling molecules are those that can be received and read by a cell through a receptor molecule on its surface. Once the signalling molecules connect with a receptor, their union sets off a process that leads to the receiving cell changing its behaviour. The sequence of events that follows involves a signalling pathway, which is a group of molecules that work together, one molecule activating the next until a specific function is carried out, such as renewing an organ's cells. There are many such signalling pathways.
However, in the case of metastatic breast cancer, a disruptive pathway is formed. The signalling molecule, also known as a ligand, connects with a receptor molecule on certain bone cells and activates a cellular pathway that ultimately disrupts healthy bone renewal. Kang's team identified the signalling molecule as Jagged1, and the receptor molecule as one that activates a cellular pathway known as the "Notch pathway."
This finding gives cancer researchers a specific target, Kang said - that of developing ways "to neutralise Jagged1's destructive power" and keeping it from interfering with normal bone growth.
At the Memorial Sloan-Kettering Cancer Centre in New York City, Jacqueline Bromberg, a physician who also studies breast cancer, said the findings of Kang's team are promising.
"The bone is the most common site for metastasis in patients with breast cancer," said Bromberg, who met Kang several years ago while he was a postdoctoral fellow at Sloan-Kettering. She noted that although there are treatments that can slow these tumours, such as oestrogen-blockers, radiation and chemotherapy, "we have few therapies which effectively eradicate bone metastasis."
At the Indiana University School of Medicine in Indianapolis, oncology professor Theresa Guise said the Princeton discoveries "show critical interactions between the tumour cells and bone cells." She added that the team has made a valuable contribution to research in that it "has dissected the contribution of the tumour and the micro-environment in this process."
The research builds on earlier work begun six years ago by Kang's laboratory that looked at how several different signalling pathways promote the spread of cancer to the bone. In a study published in the journal Nature Medicine in 2009, Kang showed that a pathway known as TGF beta plays a role in the growth of bone tumours. However, until the recent study, it was not clear that Jagged1 plays a crucial role in that process. Before the current work focused on identifying the series of interconnected events that create the network of destructive pathways, Kang and Nilay Sethi, a dual degree student who recently finished his Ph.D. in molecular biology at Princeton, worked to find first which of the signalling molecules were at work in patients with breast cancer that had metastasised to the bone.
"It turned out that tumour samples from patients with breast cancer that had spread to the bone had higher levels of Jagged1," said Sethi, who is now completing his medical degree at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School.
The current research shows that, when the Jagged1 signalling molecule binds to its receptor molecule on the bone-producing cells, the interaction turns on the signalling pathway called Notch, and that leads to dramatic changes in bone growth. "It's like a key finding its matching lock, and opens a floodgate of information," Kang said. "Unfortunately, in this case, the Jagged1-Notch signalling is misused by cancer cells to serve a destructive purpose."
In healthy bone, specialised bone cells called osteoclasts scour the bone surface and use a combination of enzymes and acids to break down the old bone. Then another group of bone cells called osteoblasts deposit a new layer of bone matrix to rebuild the bone tissue. Working just like cellular excavators and paving machines, the bone-scrubbing osteoclasts and bone-building osteoblasts work in sync every day to renew the bone and maintain its strength. When these cells' activity gets out of balance, bone diseases can result.
While tumour cells lack the specialised tools that osteoclasts have to break down the bone, they are able to use the destructive Jagged1 molecule to disrupt the balanced activity of bone renewal, forcing the osteoclasts and osteoblasts to behave in a way that allows the tumour cells to invade the bone, Kang explained.
For example, by activating Notch signalling in osteoclasts, Jagged1 makes osteoclasts mature more quickly from their precursor cells, known as monocytes. A massive accumulation of these bone-scouring osteoclasts becomes the front line of the invasive force of tumour cells.
That speeds up the breakdown of bone tissue and clears the way for tumour cells to expand into a malignant mass in the bone.
"Meanwhile, Jagged1 instructs the osteoblasts to secrete elevated levels of Interleukin-6, a tumour growth factor, so the cancer grows even faster," Kang said. "It's a one-two punch."
Creating further damage, the breakdown of the bone matrix releases a large quantity of another protein called TGF-beta, another signalling molecule that is embedded in the bone matrix during the bone-building process. In their earlier work published in 2009, Kang and colleagues showed that the TGF-beta protein derived from bones fuels the malignant growth of bone metastasis.
In the current study, some experiments conducted by Sethi established a surprising new link between TGF-beta and the Jagged1 molecule in bone metastasis.
"When tumour cells use the hijacked osteoclasts to break down the bone and release TGF-beta, it signals back to tumour cells to further stimulate the expression in Jagged1 in tumour cells," Sethi said. "The link between the Jagged1/Notch and TGF-beta pathways establishes a vicious cycle, essentially driving the unstoppable expansion of tumours and the destruction of skeletal tissues."
As a medical student, Sethi said he is acutely aware of the consequence of bone metastasis. "These patients suffer a lot. They have fractures, severe bone pain and debilitating nerve compression," he said. In addition, as the bone breaks down, calcium builds up in the blood, causing other life-threatening complications.
The key to stopping the process appears to be finding a way to neutralise the Jagged1 signalling molecule or its receptor Notch.
Kang has several ideas on how scientists may learn how to do just that. One way to interrupt the destructive process is to put a roadblock in the Notch pathway. There is a way to do that by halting the activity of gamma secretase - an enzyme that plays a key role when the Notch pathway is activated - because without it the delivery of instructions to bone cells cannot be completed. The pharmaceutical firm Merck & Co. has developed one such experimental drug that stops gamma secretase, known as a gamma secretase inhibitor or GSI, and the company has provided it to Kang's lab to support his team's work.
The drug has already shown promise treating metastatic bone cancer, Kang said. In animal experiments, the inhibitors have been proven to block the disease-causing signalling between tumour cells and bone cells, communication mediated by Jagged1 and Notch. Kang said GSI can reduce bone metastasis significantly, along with a dramatic reduction of bone destruction.
He hopes his team's new data showing that GSIs appear to work to halt the spread of cancer to the bone will result in clinicians starting a clinical trial of GSI to fight breast cancer metastases in the near future.
According to Kang, there are few drugs currently available to relieve symptoms associated with bone metastases, and none is able to completely stop the cancer. If Kang's findings lead to a drug that can halt or slow this process, it could affect the 200 000 patients that the NCI estimates are diagnosed every year with breast cancer. It might work for some other cancer patients as well, Kang said.
Sloan-Kettering's Bromberg said Kang's recent discovery "underlies the importance of targeting the environmental milieu" in which disease develops, in this case the activity of the Notch signalling pathway and specific interactions between cancer cells and the specialised cells that break down and rebuild bone.
Kang's work was funded by the New Jersey Commission on Cancer Research, the San Francisco-based Brewster Foundation founded by 1969 Princeton alumnus Leonard Schaeffer, US Department of Defence, American Cancer Society, Merck & Co., the National Institutes of Health and the Champalimaud Foundation in Lisbon, Portugal.
* Full caption:
Breast cancer's spread to the bone relies on interactions among tumour cells (blue); specialised bone cells that break down the bone, called osteoclasts (pink); specialised cells that rebuild bone tissue, called osteoblasts (brown); and the bone matrix. A "signalling protein" called Jagged1 sends destructive instructions that activate a group of molecules that work together, one molecule activating the next, in what's called the "Notch signalling pathway" (green flash) in the bone cells. Notch signalling stimulates the bone degrading activity of osteoclasts, releasing tumour growth factors such as the TGF-beta protein (red bubbles) from the bone matrix. Meanwhile, Notch signalling in bone-building osteoblasts increases the expression of another secreted protein, IL-6 (orange bubbles), which feeds back to tumour cells to promote their growth, forming a vicious cycle in bone metastasis. (Illustration: Stephen Cheng)
Source: Princeton University
